Why One Diabetes Threshold Does Not Fit Every Population

A single fasting glucose number does not carry the same meaning for everyone. Two people from different backgrounds can post identical lab values while sitting at very different distances from diabetes, because the machinery that produces that number is calibrated differently across the world's populations. That is the practical problem with one global threshold: applied without context, it can overlook people who are genuinely at risk and worry people who are not.

This is well-established physiology, not a fringe claim, and it shapes how clinicians screen, diagnose, and counsel. Anyone with questions about their own glucose results should speak with a clinician who can see the whole picture.

Key points#

• Glucose control depends on two systems: how sensitive tissues are to insulin, and how much insulin the pancreas secretes to compensate.
• The same glucose value can be reached by different combinations of these two systems, so the number alone hides what is actually happening.
• Population studies show the sensitivity-secretion balance sits in different places on average across ethnic groups.
• Because common cutoffs were calibrated mostly in one population, some health systems now use lower body-mass thresholds for South Asian and East Asian patients.
• Population averages describe groups, not individuals, and never replace measuring the person in front of you.

Two systems behind a single reading#

It helps to think of glucose control as two systems working in tandem rather than one gauge. The first is insulin sensitivity: how readily muscle, liver, and fat pull glucose out of the blood when insulin signals them to. The second is insulin secretion, also called beta-cell function: how much insulin the pancreas releases to get that job done.

In a healthy person these two are coupled tightly. When sensitivity drops, the pancreas answers by secreting more, and glucose stays in range. The relationship is curved rather than straight; researchers often model it as a hyperbola, and the product of the two measures, the disposition index, gives a rough read on how well the whole system is coping. Type 2 diabetes tends to emerge when the pancreas can no longer raise its output fast enough to cover falling sensitivity. The system built to compensate simply runs out of headroom.

Here is the catch. A fasting glucose value, and even a single oral glucose tolerance test, cannot tell you which of these two systems is carrying the load. Consider two people with the same reading. One might be markedly insulin resistant but paired with a pancreas that compensates hard. The other might be quite insulin sensitive yet secreting relatively little. They look identical on the lab slip, and their situations are not alike at all.

What population studies actually show#

Line up measurements from around the world and the coupling between sensitivity and secretion does not land in the same spot for every group. Some populations, on average, show lower insulin sensitivity for a given body size, with the pancreas compensating through higher output. Others sit toward the opposite end, more sensitive but with a more modest secretory response. East Asian populations, for example, have repeatedly shown comparatively lower insulin responses, while several South Asian groups show pronounced insulin resistance. These are averages with wide individual scatter, not labels that predict any single person.

A 2013 systematic review and meta-analysis in Diabetes Care set out to map this directly. It pooled studies that measured insulin sensitivity and insulin response across ethnic groups and examined how the two related from one population to the next. The consistent finding was that the sensitivity-secretion relationship is not one universal curve. It shifts by population.

That shift has a clinical edge. If diagnostic cutoffs, risk calculators, and body-mass-index thresholds were derived largely in one population, they will not translate cleanly to another. This is part of why some health systems now apply lower BMI thresholds to flag diabetes risk in South Asian and East Asian patients. A 2015 analysis in Diabetes Care, for instance, argued for a lower screening cut point in Asian Americans, whose risk rises at a body mass that would look reassuring on a standard chart. The physiology was signaling, in effect, that the same waistline carries different metabolic weight in different people.

From group averages to the individual#

None of this makes ethnicity destiny, and it is no substitute for measuring the actual patient. Population averages conceal enormous individual variation, and ethnicity is a blunt proxy for a tangle of genetic, developmental, dietary, and social factors. The honest reading is more modest and more useful: a one-size-fits-all threshold is a starting point, not a verdict, and it deserves to be held loosely when a patient's background suggests the curve sits elsewhere.

This is where precision medicine earns the label. The aim is not to trade one rigid cutoff for a stack of rigid cutoffs sorted by group. It is to measure both systems where feasible, weigh the patient's context, and stop treating a lone glucose number as the whole story. The fuller the picture, the earlier and more accurately clinicians can identify the people whose pancreas is losing its ability to compensate, often years before a standard test crosses the diagnostic line.

For a generalist in family or internal medicine, the takeaway is practical. Reading the evidence carefully, and knowing where a threshold came from, is part of applying it well. A screening rule built for one population is a tool to use with judgment, not a rule to follow blindly.